The family tree of pharmaceutical pricing is in full bloom...
...and winning strategies translate relevant medical data into meaningful value propositions for payers' budgetary planning security. Contact us to learn more! #HTA #Pricing #Pharmamarket
top of page
BLOG
- Jul 10, 2019
European pharma markets: is HTA the new marketing?
Marketing is always the art of differentiating products in such a way that the benefits are apparent to customers. HTA assessments formalise the value assessment of innovations since more than twenty years. But there is still a long way to go to integrate all clinical and real life evidence to demonstrate "value for money" to payers. Big data driven approaches to capture value data is one novel way to enrich Health Technology Assessment dossiers to improve the odds of a holis
- Jul 1, 2019
HTA for 10% of the world population influence pharmaceutical pricing...
...for 80% of the world's population. The biggest pharma market of the world, the US, represents 40% of the world's pharma market...and 5% of the world's population and contributes the largest proportion of pharmaceutical R&D and innovation. #HTA #Pricing #Pharmamarket
- Jun 4, 2019
Health Technology Assessment: the organisation differs - the basic assessment principles are the sam
...while the way social consensus is built in Health Technology appraisals varies. #HTA
- Jun 3, 2019
Vienna School of Clinical Research Course May 2019: Should patients be involved in Health Technology
...if yes, how? If no, why not? Course participants from across the globe discussed the question and shared their views. #HTA #VSCR
bottom of page